A Growth Differentiation Factor 15 Receptor Agonist in Randomized Placebo-Controlled Trials in Healthy or Obese Persons
The prolonged half-life of MBL949 supports biweekly dosing in patients. MBL949 had an acceptable safety profile. The robust weight loss observed in nonclinical species did not translate to weight loss efficacy in humans.
Authors
- Kurt A. Heldwein (ORCID: https://orcid.org/0009-0007-8905-1347)
- Ryan S. Streeper (ORCID: https://orcid.org/0009-0007-3429-988X)
- Joanna Jamontt (ORCID: https://orcid.org/0009-0005-4795-675X)
- Yanling He (ORCID: https://orcid.org/0000-0002-1535-6726)
- Jill Kompa (ORCID: https://orcid.org/0000-0002-2581-1294)
- Allison B. Goldfine (ORCID: https://orcid.org/0000-0002-0345-1048)
- J. Paul Schofield (ORCID: https://orcid.org/0000-0002-7261-3565)
- Eleftheria Maratos–Flier (ORCID: https://orcid.org/0000-0002-5712-5643)
- Aimee Usera (ORCID: https://orcid.org/0009-0009-0288-0199)
- Mark Kagan (ORCID: https://orcid.org/0009-0002-1776-0172)
- William B. Smith (ORCID: https://orcid.org/0000-0002-6907-9031)
- Christopher J. O’Donnell (ORCID: https://orcid.org/0000-0002-2667-8624)
- Linh Vong (ORCID: https://orcid.org/0009-0002-9105-4292)
- Chad D. Schwartzkopf (ORCID: https://orcid.org/0009-0001-0333-2807)
- D. Le Nguyen (ORCID: https://orcid.org/0009-0005-8562-1977)
- Timothy M. Clough (ORCID: https://orcid.org/0009-0005-5215-0873)
- Joseph D. Layne
Institutions
- Novartis (Switzerland) (CH)
- Altasciences (Canada) (CA)
- Alliance for Multispecialty Research (United States) (US)
- Novartis (United States) (US)
- Tris Pharma (United States) (US)
Publication Details
- Journal
- The Journal of Clinical Endocrinology & Metabolism
- Published
- 2024-08-16
- DOI
- https://doi.org/10.1210/clinem/dgae550
- Citations
- 17
- Primary Topic
- GDF15 and Related Biomarkers
- Type
- article
- Field-Weighted Citation Impact
- 7.99